May 12, 2014 11:20am EDT OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
Apr 22, 2014 3:06pm EDT OPKO Announces Presentation of Data on Long-Acting Oxyntomodulin at Diabetes Conference
Apr 17, 2014 11:22am EDT OPKO Acquires Next Generation Dry Powder Inhaler to Treat Respiratory Disorders